ABPI appoints former AZ innovation head
pharmafile | June 17, 2010 | Appointment | Research and Development, Sales and Marketing | ABPI, appointment, research and development, sales and marketing
UK industry association the ABPI has appointed Carol Blount as its new head of commercial affairs.
Carol has more than 15 years’ senior leadership experience within UK pharma, most recently as head of innovation for AstraZeneca where she led a number of initiatives including joint working projects with industry and PCTs
Prior to this she worked for Bayer and her experience includes leadership of strategic innovation and change, business development and brand marketing leading to increased sales and contribution
“With a new Government and an uncertain financial situation throughout the world, these are challenging times for our industry,” said Carol. “I am very much looking forward to working in my new role to help tackle some of the vitally important issues facing the industry.”
In her new role, she will be responsible for managing all commercial affairs and initiatives within the ABPI, including NHS Joint Working and quality, innovation, prevention and productivity (QIPP) initiatives, delivery of commercial aspects of the PPRS, supply chain and distribution initiatives.
Related Content
The November 2020 issue of Pharmafocus is available to read free online now!
The latest monthly edition of Pharmafocus is available to read for free online now!
UK life sciences industry does not want no-deal Brexit, says ABPI Chief
Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a …
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …